51 completed, 18 terminated, 8 active not recruiting, 5 withdrawn. 83 Phase 1, 22 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 83 | Completed 51, Terminated 18, Active not recruiting 8, Withdrawn 5, Recruiting 1 |
| Phase 2 | 22 | Completed 13, Terminated 5, Active not recruiting 2, Withdrawn 2 |
Follow Recurrent Marginal Zone Lymphoma: new trials by email Literature Review of Recurrent Marginal Zone Lymphoma trials Research Report on Recurrent Marginal Zone Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies Autologous BAFFR-targeting CAR T Cells, Bendamustine, Biopsy - B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia | Phase 1 | Recruiting | Mayo Clinic | 27 | 2024-03-18 | 2026-02-13 |
| Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma Lenalidomide, Ublituximab, Umbralisib - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Phase 1 | Withdrawn | Yazeed Sawalha | 2022-09-30 | 2022-09-30 | |
| Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin Lymphoma Acalabrutinib, Duvelisib - Recurrent Follicular Lymphoma, Recurrent Marginal Zone Lymphoma | Phase 1 | Withdrawn | Narendranath Epperla | 2022-07-01 | 2022-06-07 | |
| CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL CpG-STAT3 siRNA CAS3/SS3, Radiation Therapy - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Withdrawn | City of Hope Medical Center | 2021-07-27 | 2024-04-25 | |
| CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma Lenalidomide, Obinutuzumab, Oral Azacitidine - Indolent B-Cell Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 | Completed | Joseph Tuscano | 8 | 2020-10-23 | 2025-04-24 |
| An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment Venetoclax, Lenalidomide, Rituximab - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Follicular Lymphoma | Phase 1 | Active not recruiting | Thomas Jefferson University | 4 | 2020-10-16 | 2026-10-02 |
| Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma Carmustine, Cytarabine, Etoposide - Hematopoietic Cell Transplantation Recipient, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Completed | Ohio State University Comprehensive Cancer Center | 19 | 2018-09-10 | 2025-05-14 |
| Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma Ibrutinib, Laboratory Biomarker Analysis, Pevonedistat - B-Cell Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia | Phase 1 | Completed | City of Hope Medical Center | 18 | 2018-04-27 | 2026-11-10 |
| A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Laboratory Biomarker Analysis - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Active not recruiting | Fred Hutchinson Cancer Center | 53 | 2017-12-05 | 2026-06-22 |
| Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma Cryosurgery, Dendritic Cell Therapy, Laboratory Biomarker Analysis - Aggressive Non-Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Completed | Mayo Clinic | 11 | 2017-08-15 | 2026-05-04 |
| Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma Selinexor - Diffuse Large B-Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Active not recruiting | Barbara Ann Karmanos Cancer Institute | 43 | 2017-06-20 | 2026-10-23 |
| Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Lenalidomide, Obinutuzumab, Venetoclax - B-Cell Lymphoma, Unspecified, Grade 1 Follicular Lymphoma | Phase 1 | Active not recruiting | Beth Christian | 22 | 2017-02-21 | 2026-09-24 |
| Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma Laboratory Biomarker Analysis, Lenalidomide, Nivolumab - Grade 3a Follicular Lymphoma, Recurrent Burkitt Lymphoma | Phase 1 / Phase 2 | Completed | David Bond, MD | 36 | 2017-02-14 | 2026-09-23 |
| Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Ibrutinib, Laboratory Biomarker Analysis, Pembrolizumab - B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma, Grade 1 Follicular Lymphoma | Phase 1 | Completed | Kami Maddocks | 2 | 2017-01-12 | 2019-07-30 |
| Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma Blinatumomab, Lenalidomide - Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 35 | 2016-11-15 | 2025-11-26 |
| Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma rituximab, lenalidomide, romidepsin - B-cell Adult Acute Lymphoblastic Leukemia, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Phase 1 / Phase 2 | Withdrawn | Mayo Clinic | 2016-10-01 | 2016-08-11 | |
| CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma 6,8-bis(benzylthio)octanoic acid, bendamustine hydrochloride, rituximab - B-cell Adult Acute Lymphoblastic Leukemia, B-cell Chronic Lymphocytic Leukemia | Phase 1 | Terminated | Wake Forest University Health Sciences | 1 | 2014-12-01 | 2018-07-02 |
| Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes, Bendamustine Hydrochloride, Cyclophosphamide - B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma, B-Cell Prolymphocytic Leukemia | Phase 1 | Active not recruiting | City of Hope Medical Center | 37 | 2014-10-14 | 2026-10-26 |
| A Phase I/II Study of Intratumoral Injection of SD-101 Ipilimumab, SD-101, Radiation therapy - Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma | Phase 1 / Phase 2 | Completed | Robert Lowsky | 9 | 2014-09-01 | 2019-11-27 |
| Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection Ibrutinib, Laboratory Biomarker Analysis, Pharmacological Study - Adult B Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia | Phase 1 | Terminated | National Cancer Institute (NCI) | 72 | 2014-09-01 | 2015-08-20 |
Showing 20 of 83. Sign in to see all of them.
Lymphoma, B-Cell, Marginal Zone (83) · Lymphoma, Follicular (82) · Lymphoma, Mantle-Cell (73) · Leukemia, Lymphocytic, Chronic, B-Cell (67) · Lymphoma, Large B-Cell, Diffuse (65) · Lymphoma, Non-Hodgkin (59) · Waldenstrom Macroglobulinemia (57) · Burkitt Lymphoma (53) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (49) · Lymphoma, Large-Cell, Immunoblastic (44) · Hodgkin Disease (34) · Lymphoma, Large-Cell, Anaplastic (34) · Mycosis Fungoides (34) · Sezary Syndrome (34) · Lymphoma, T-Cell, Cutaneous (33)
Hemic and Lymphatic Diseases (83) · Immune System Diseases (83) · Immunoproliferative Disorders (83) · Lymphatic Diseases (83) · Lymphoma (83) · Lymphoproliferative Disorders (83) · Neoplasms (83) · Neoplasms by Histologic Type (83) · Hematologic Diseases (77) · Lymphoma, B-Cell (72) · Leukemia (68) · Chronic Disease (67) · Disease Attributes (67) · Leukemia, B-Cell (67) · Leukemia, Lymphoid (67)
Rituximab (18) · Lenalidomide (13) · fludarabine phosphate (9) · Bortezomib (8) · Bendamustine Hydrochloride (6) · Cyclophosphamide (5) · Vorinostat (5) · ibrutinib (5) · tanespimycin (5) · Flow Cytometry (4) · Peripheral Blood Stem Cell Transplantation (4) · Biopsy (3) · CTLA-4 Antigen (3) · Cyclosporine (3) · Etoposide (3)
National Cancer Institute (NCI) (43) · Fred Hutchinson Cancer Center (7) · City of Hope Medical Center (6) · Mayo Clinic (5) · Case Comprehensive Cancer Center (2) · Kami Maddocks, MD (2) · Robert Lowsky (2) · Amir Mortazavi (1) · Barbara Ann Karmanos Cancer Institute (1) · Beth Christian (1) · David Bond, MD (1) · Joseph Tuscano (1) · Kami Maddocks (1) · M.D. Anderson Cancer Center (1) · Morphotek (1)
United States (78) · Canada (4) · Italy (2) · Germany (1)
Kami Maddocks, MD (4) · Ajay Gopal (3) · John Byrd (2) · Joseph M Tuscano (2) · Patricia LoRusso (2) · Ramesh Ramanathan (2) · Tanya Siddiqi (2) · Thomas Witzig (2) · Adam Petrich, MD (1) · Alexey Danilov (1) · Amir Mortazavi, MD (1) · Antonius Miller (1) · Beth A Christian (1) · Beth Christian, MD (1)
PMID 32499241, PMID 34515338, PMID 22259028, PMID 22308288, PMID 23256542, PMID 24241210, PMID 24474568, PMID 24530971, PMID 25355819, PMID 26943915, PMID 27118452, PMID 28270022, PMID 28314788, PMID 29292843, PMID 29572391, PMID 31388792, PMID 31617432, PMID 33492438, PMID 33785483, PMID 34320785, PMID 34492703, PMID 34780125, PMID 36631449, PMID 39161543
U01CA076576 (9), P30CA015083 (5), P30CA016058 (5), U01CA062487 (5), U01CA062491 (5), U01CA062505 (5), U01CA099168 (5), U01CA062502 (4), P30CA015704 (3), P30CA033572 (3), P50CA107399 (3), U01CA069912 (3), U01CA132123 (3), P01CA044991 (2), P30CA022453 (2)